Newshot
Account

Anthropic bought a one-person, AI-powered biotech: is this drug discovery’s future?

Source: Nature Published: AI Reprinted 中文 AIAnthropic
Summary

Nature, Published online: 11 November 2026; doi:10.1038/d41586-026-03640-9 A promising biotechnology company developed a new approach that might treat a rare disease — but its sole employee didn’t do all the work.

Original text(via Nature)
A man wearing glasses uses a laptop in a dimly lit office, with shelves of folders lining the wall behind
A man wearing glasses uses a laptop in a dimly lit office, with shelves of folders lining the wall behind

Minimalist biotechnology companies that have just a handful of employees — or even as few as one — are becoming more feasible with the rise of artificial-intelligence tools.Credit: Getty

How many scientists does it take to discover a drug?

The question came to the fore after news that a biotechnology company armed with an artificial-intelligence assistant, two promising drug leads and just one full-time human employee had been acquired by San Francisco-based Anthropic as part of the AI giant’s expansion into biomedical science.

AI agents run this automated biology lab that sequences DNA and more

In truth, it took many human scientists to develop the molecules that are the mini-company’s star products: two antibodies that are still in the early stages of development and were designed to treat a rare form of muscular dystrophy. The company, Mithril Medicine in Cambridge, Massachusetts, also hired part-time consultants to advise on the project, and paid at least five contract research organizations to conduct experiments. Many more researchers will be needed to carry the drug further, especially if it eventually enters clinical trials. “It takes a village to develop a drug,” says Jeb Keiper, a partner at Third Rock Ventures, a venture-capital firm in Boston, Massachusetts.

But the news sparked a wave of discussions about whether the one-person biotech is the drug-discovery business model of the future. “We will see more and more of these small teams that are enabled by AI,” says James Zou, a computer scientist who works on biomedical applications of AI at Stanford University in California. “They will be very powerful for identifying good opportunities and moving quickly.”

Pint-sized powerhouses

Itsy-bitsy biotechs are not a new concept. Entrepreneur Matt Davidson started his first biotech company in 2013, nearly a decade before ChatGPT’s public debut. Davidson kept the roster trim for years, with only two full-time employees until the drug he was developing was ready to enter late-stage clinical testing. The company never had a physical laboratory, Davidson says. All the lab work was contracted out.

His current company, Azora Therapeutics in Los Angeles, California, has a whopping five employees. He uses AI more for summarizing reports than for scientific discovery and says that AI tools have made tiny biotechs more efficient. “We use consultants a little bit less than we used to,” he says.

Anthropic’s AI biolab finds ‘CRISPR-like’ DNA in viruses. What’s next?

Mithril Medicine leaned more heavily on AI than Azora does, and tasked Anthropic’s AI assistant Claude with helping to analyse data and suggesting next steps, as well as taming the piles of emails and paperwork that come from working with multiple contract research organizations. “What began as an exercise in staying lean evolved into the thesis for an entirely new operating model, which we now call Pipeline-in-a-Person,” wrote Cody Tranbarger, Mithril’s former chief executive and lone employee, on LinkedIn. (Tranbarger, who works for Anthropic since Mithril was absorbed into it, declined to speak to Nature, as did Anthropic.)

Enjoying our latest content? Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research

doi: https://doi.org/10.1038/d41586-026-03640-9

References

  • Zhang, H. G., Eckmann, P., Miao, J., Mahon, A. B. & Zou, J. Science 394, eaeg6779 (2026).Article Google Scholar

Zhang, H. G., Eckmann, P., Miao, J., Mahon, A. B. & Zou, J. Science 394, eaeg6779 (2026).

Article Google Scholar

Download references

Reprints and permissions

Related Articles

  • Four ways to power-up AI for drug discovery
  • Are AI tech giants hijacking drug discovery?
  • Understanding the company landscape in AI-driven biopharma R&D
  • AI-powered innovation in drug discovery

Subjects

  • Biotechnology
  • Drug discovery
  • Machine learning

Latest on:

  • Biotechnology
  • Drug discovery
  • Biotech innovations are an opportunity to limit climate change Editorial 11 NOV 26

Biotech innovations are an opportunity to limit climate change

Editorial 11 NOV 26

  • Engineered bacteria are weaning farms away from synthetic fertilizers News 11 NOV 26

Engineered bacteria are weaning farms away from synthetic fertilizers

News 11 NOV 26

  • Cholera bacterium’s good deed: inspiring a glue with rare properties Research Highlight 06 NOV 26

Cholera bacterium’s good deed: inspiring a glue with rare properties

Research Highlight 06 NOV 26

  • AI’s energy paradox: will the AI boom strain energy systems or be the source of solutions? Spotlight 11 NOV 26

AI’s energy paradox: will the AI boom strain energy systems or be the source of solutions?

Spotlight 11 NOV 26

  • PhDs worldwide are having a shake up — why now? Career Feature 10 NOV 26

PhDs worldwide are having a shake up — why now?

Career Feature 10 NOV 26

  • Biotech firms are meant to pay to use Earth’s genetic data. They’re not. News 03 NOV 26

Biotech firms are meant to pay to use Earth’s genetic data. They’re not.

News 03 NOV 26

  • UNC13A splice correction rescues synaptic dysfunction induced by TDP-43 loss Article 11 NOV 26

UNC13A splice correction rescues synaptic dysfunction induced by TDP-43 loss

Article 11 NOV 26

  • Domain-alteration chimeras rewire oncogenic complexes in prostate cancer Article 11 NOV 26

Domain-alteration chimeras rewire oncogenic complexes in prostate cancer

Article 11 NOV 26

  • In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering Article 06 NOV 26

In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering

Article 06 NOV 26

Jobs

  • Associate or Senior Editor, Communications AI & Computing Job Title: Associate or Senior Editor, Communications AI & Computing Locations: Shanghai, Beijing, Pune, New Delhi, Berlin or Madrid (hybrid) Appli... Shanghai, Beijing, Pune, New Delhi, Berlin or Madrid (hybrid) Springer Nature Ltd

Associate or Senior Editor, Communications AI & Computing

Job Title: Associate or Senior Editor, Communications AI & Computing Locations: Shanghai, Beijing, Pune, New Delhi, Berlin or Madrid (hybrid) Appli...

Shanghai, Beijing, Pune, New Delhi, Berlin or Madrid (hybrid)

Springer Nature Ltd

  • Postdoctoral Fellow Postdoctoral Fellow focus on ferroic smart materials: shape-memory alloys, piezoelectric ceramics, and magnetostrictive materials, etc Ningbo, Zhejiang (CN) Center for Advanced Smart Materials (CASM), Yongjiang Laboratory (Y-Lab)

Postdoctoral Fellow

Postdoctoral Fellow focus on ferroic smart materials: shape-memory alloys, piezoelectric ceramics, and magnetostrictive materials, etc

Ningbo, Zhejiang (CN)

Center for Advanced Smart Materials (CASM), Yongjiang Laboratory (Y-Lab)

  • Principal Investigator/ Associate Professor PI & Associate Professor class focus on innovative research about ferroic smart materials or technology transfer Ningbo, Zhejiang (CN) Center for Advanced Smart Materials (CASM), Yongjiang Laboratory (Y-Lab)

Principal Investigator/ Associate Professor

PI & Associate Professor class focus on innovative research about ferroic smart materials or technology transfer

Ningbo, Zhejiang (CN)

Center for Advanced Smart Materials (CASM), Yongjiang Laboratory (Y-Lab)

  • Open-Rank Faculty Position in Basic Biomedical Research WashU Medicine’s Dept of Anesthesiology seeks applicants for a tenure-track or tenured faculty position in the Division of Basic Research. Saint Louis, Missouri WashU Medicine - Anesthesiology

Open-Rank Faculty Position in Basic Biomedical Research

WashU Medicine’s Dept of Anesthesiology seeks applicants for a tenure-track or tenured faculty position in the Division of Basic Research.

Saint Louis, Missouri

WashU Medicine - Anesthesiology

  • Global Recruitment of Outstanding Young Talents We are seeking exceptional candidates who qualify for the National Science Fund for Excellent Young Scholars (Overseas) 1068 Xueyuan Avenue, Shenzhen 518055 P. R. China Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences（CAS)

Global Recruitment of Outstanding Young Talents

We are seeking exceptional candidates who qualify for the National Science Fund for Excellent Young Scholars (Overseas)

1068 Xueyuan Avenue, Shenzhen 518055 P. R. China

Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences（CAS)

The text above was extracted automatically from the source page and may miss images, tables or code blocks. The original is authoritative.

Published by Nature
This site only summarises and aggregates; copyright stays with the original author. Headlines and summaries follow the source — where they differ, the original wins.
Read the original ↗